Drug Interactions between Berkley and Jensen Acid Reducer Maximum Strength and dalfampridine

MONITOR: Coadministration with inhibitors and/or substrates of organic cation transporter 2 (OCT2) may increase the plasma concentrations of dalfampridine. In vitro studies have shown that OCT2 is the primary transporter responsible for the active tubular secretion of dalfampridine, which accounts for approximately 60% of its renal elimination - the major route of clearance for dalfampridine. When a single 10 mg dose of dalfampridine was administered to 23 healthy volunteers with the OCT2 inhibitor cimetidine (400 mg every 6 hours), dalfampridine systemic exposure (AUC) was 25% higher relative to the reference value. The interaction has not been studied with OCT2 substrates, but competitive inhibition for active tubular secretion is possible. Elevated plasma levels of dalfampridine may increase the risk of adverse effects, particularly seizures.

MANAGEMENT: Caution is advised when dalfampridine is used with OCT2 inhibitors and/or substrates. The potential benefits of concomitant use should be considered against the risk of seizures.